Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Copper-64-labeled daratumumab PET/CT: a potential imaging technique for MM

Amrita Krishnan • 7 Dec 2019
ASH 2019
Multiple Myeloma Antibodies Daratumumab

Amrita Krishnan, MD, City of Hope Medical Center, Duarte, CA, explains the first-in-human imaging of multiple myeloma using copper-64-labeled daratumumab (NCT03311828). This phase I trial showed that tracing multiple myeloma dissemination using daratumumab, a CD-38 directed antibody, radioconjugated with cooper-64 via the chelator DOTA, led to improved sensitivity and specificity when compared with fluoro-deoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Amrita Krishnan

0:49
Management of patients with penta-class refractory myeloma
Amrita Krishnan • 11 Dec 2023
1:01
Considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
Amrita Krishnan • 11 Dec 2023
0:50
Dose modifications of talquetamab to manage AEs in patients with multiple myeloma
Amrita Krishnan • 11 Dec 2023
1:15
How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myeloma
Amrita Krishnan • 29 Sep 2022

Related Videos

3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
1:48
Tackling underrepresentation of minorities in CAR-T clinical trials
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals